Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells

Cancer

Volumn 117, Issue 13, 2011, Pages 2926-2938

  Sandulache, Vlad C ^a,b   Ow, Thomas J ^b   Pickering, Curtis R ^b   Frederick, Mitchell J ^b   Zhou, Ge ^b   Fokt, Izabela ^b   Davis Malesevich, Melinda ^a   Priebe, Waldemar ^b   Myers, Jeffrey N ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

2 deoxyglucose; glutamine; glycolysis; metabolism; reducing potential

Indexed keywords

ADENOSINE DIPHOSPHATE; DEOXYGLUCOSE; FLUORIDE; GLUCOSE; GLUTAMINE; LACTIC ACID; PENTOSE PHOSPHATE; PROTEIN P53;

AMINO ACID METABOLISM; ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; CELL DEATH; CELL ENERGY; CELL METABOLISM; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CITRIC ACID CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLYCOLYSIS; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLOMICS; PHENOTYPE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; WILD TYPE;

ADENOSINE TRIPHOSPHATE; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; DEOXYGLUCOSE; DISEASE PROGRESSION; GENES, P53; GLUCOSE; GLUTAMINE; HEAD AND NECK NEOPLASMS; HUMANS; LACTIC ACID; MASS SPECTROMETRY; METABOLOMICS; METFORMIN; NEOPLASMS, SQUAMOUS CELL; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959588949     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25868     Document Type: Article

References (45)

1. Vander Heiden MG, Cantley LC, Thompson CB., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029-1033.
2. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007; 104: 19345-19350.
3. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008; 105: 18782-18787.
4. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y., Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007; 178: 93-105. (Pubitemid 47026405)
5. Pignon JP, le Maitre A, Maillard E, Bourhis J., Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92: 4-14.
6. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ., Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009; 69: 7986-7993.
7. Maschek G, Savaraj N, Priebe W, et al. 2-Deoxy-D-glucose increases the efficacy of Adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 2004; 64: 31-34. (Pubitemid 38114078)
8. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM., Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007; 7: 3-18. (Pubitemid 46062402)
9. McFate T, Mohyeldin A, Lu H, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem. 2008; 283: 22700-22708.
10. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001; 51: 349-353. (Pubitemid 32884281)
11. Estilo CL, P Oc, Talbot S, et al. Oral tongue cancer gene expression profiling: identification of novel potential prognosticators by oligonucleotide microarray analysis [serial online]. BMC Cancer. 2009; 9: 11.
12. Reisser C, Eichhorn K, Herold-Mende C, Born AI, Bannasch P., Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer. 1999; 80: 194-198. (Pubitemid 29001721)
13. Waitzberg AF, Nonogaki S, Nishimoto IN, et al. Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas. Cancer Detect Prev. 2004; 28: 178-186. (Pubitemid 38836825)
14. Bhattacharya N, Roy A, Roy B, Roychoudhury S, Panda CK., MYC gene amplification reveals clinical association with head and neck squamous cell carcinoma in Indian patients. J Oral Pathol Med. 2009; 38: 759-763.
15. Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res. 2003; 63: 1179-1182. (Pubitemid 36348691)
16. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 2000; 275: 21797-21800. (Pubitemid 30621745)
17. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N., Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol. 2008; 32: 101-111. (Pubitemid 351176067)
18. Stokkel MP, ten Broek FW, van Rijk PP., The role of FDG-PET in the clinical management of head and neck cancer. Oral Oncol. 1998; 34: 466-471. (Pubitemid 28546859)
19. Mohanti BK, Rath GK, Anantha N, et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys. 1996; 35: 103-111. (Pubitemid 26137174)
20. Shanmugam M, McBrayer SK, Rosen ST., Targeting the Warburg effect in hematological malignancies: from PET to therapy. Curr Opin Oncol. 2009; 21: 531-536.
21. Zhu Z, Jiang W, McGinley JN, Thompson HJ,. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 2005; 65: 7023-7030. (Pubitemid 41060743)
22. Dwarakanath BS, Singh D, Banerji AK, et al. Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. J Cancer Res Ther. 2009; 5 (suppl 1): S21-S26.
23. Lampidis TJ, Kurtoglu M, Maher JC, et al. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells." Cancer Chemother Pharmacol. 2006; 58: 725-734. (Pubitemid 44351251)
24. Priebe W, Cybulski M, Fokt I, Skora S, Conrad CA, Madden T., Blocking glycolysis with 2-deoxy-D-glucose prodrugs to target brain tumors: a novel concept [abstract]. Mol Cancer Ther. 2009;8(12 suppl);282. Abstract C98.
25. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR,. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007; 67: 3364-3370. (Pubitemid 46724876)
26. Simons AL, Fath MA, Mattson DM, et al. Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys. 2007; 69: 1222-1230. (Pubitemid 47625869)
27. Lin CJ, Grandis JR, Carey TE, et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck. 2007; 29: 163-188. (Pubitemid 46167784)
28. Rago R, Mitchen J, Wilding G., DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. Anal Biochem. 1990; 191: 31-34.
29. Riccardi C, Nicoletti I., Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006; 1: 1458-1461.
30. van Genderen H, Kenis H, Lux P, et al. In vitro measurement of cell death with the annexin A5 affinity assay. Nat Protoc. 2006; 1: 363-367.
31. Ihrlund LS, Hernlund E, Khan O, Shoshan MC,. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol. 2008; 2: 94-101.
32. Hamel P, Abed E, Brissette L, Moreau R., Characterization of oxidized low-density lipoprotein-induced hormesis-like effects in osteoblastic cells. Am J Physiol Cell Physiol. 2008; 294: C1021-C1033. (Pubitemid 351507917)
33. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457: 910-914.
34. Tong X, Zhao F, Thompson CB., The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev. 2009; 19: 32-37.
35. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M., KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010; 38 (database issue): D355-D360.
36. Hernlund E, Hjerpe E, Avall-Lundqvist E, Shoshan M., Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment. Mol Cancer Ther. 2009; 8: 1916-1923.
37. Mathupala SP, Heese C, Pedersen PL., Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem. 1997; 272: 22776-22780. (Pubitemid 27386097)
38. Okoshi R, Ozaki T, Yamamoto H, et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem. 2008; 283: 3979-3987.
39. Ben Sahra I, Laurent K, Giuliano S, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010; 70: 2465-2475.
40. Ervens J, Fuchs H, Niemann VT, Hoffmeister B., Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer. J Craniomaxillofac Surg. 2008; 36: 89-94.
41. Pelicano H, Martin DS, Xu RH, Huang P., Glycolysis inhibition for anticancer treatment. Oncogene. 2006; 25: 4633-4646. (Pubitemid 44187614)
42. Maher JC, Savaraj N, Priebe W, Liu H, Lampidis TJ., Differential sensitivity to 2-deoxy-D-glucose between 2 pancreatic cell lines correlates with GLUT-1 expression [serial online]. Pancreas. 2005; 30: e34-e39.
43. Nicholson DE., Metabolic Pathways, 22nd ed. Buenos Aires, Argentina: Sigma-Aldrich S.A.; 2003.
44. Zhang XD, Deslandes E, Villedieu M, Poulain L, Duval M, Gauduchon P, et al. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro. Anticancer Res 26 (5A): 3561-3566. 2006. (Pubitemid 44701539)
45. Kurtoglu M, Gao N, Shang J, et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther. 2007; 6: 3049-3058. (Pubitemid 350206783)